EDIT - Editas Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

33.44

-1.02 (-2.96%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	34.46
Open	34.35
Bid	31.74 x 100
Ask	37.50 x 200
Day's Range	32.41 - 34.77
52 Week Range	13.12 - 45.02
Volume	801,833
Avg. Volume	1,512,261

Market Cap	1.551B
Beta	3.59
PE Ratio (TTM)	N/A
EPS (TTM)	-2.98
Earnings Date	May 14, 2018 - May 18, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	44.74

Trade prices are not sourced from all markets

All

News

Press Releases

Simply Wall St.11 hours ago
Editas Medicine Inc (NASDAQ:EDIT): What Does The Future Look Like?
Editas Medicine Inc’s (NASDAQ:EDIT) most recent earnings update in December 2017 signalled company earnings became less negative compared to the previous year’s level as a result of recent tailwinds BelowRead More...
MarketWatch6 days ago
Companies with women executives can help you do better in the stock market
Women are more likely to practice five of the nine management behaviors that McKinsey & Co. thinks are key to a company’s success.
Motley Fool21 days ago
Oops! CRISPR Concerns Turn Out to be a Big Nothingburger
The gene-editing technique is just as promising as ever. And that presents opportunities for adventurous investors.
GlobeNewswire27 days ago
Editas Medicine Names James C. Mullen as Chairman of the Board of Directors
CAMBRIDGE, Mass., March 28, 2018-- Editas Medicine, Inc., a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the Board of Directors, effective immediately.. ...
Motley Foollast month
3 Stocks That Could Double Your Money
These stocks have already doubled or come close to doing so over the past year. Here's why they could do it again.
GlobeNewswirelast month
New Research: Key Drivers of Growth for Editas Medicine, Magellan Health, The RMR Group, Marcus, Nordson, and USA Compression Partners, LP — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, March 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Motley Foollast month
3 Reasons CRISPR Stocks Could Keep Soaring
Gene-editing mania has driven these stocks to nosebleed valuations, but that doesn't mean they can't go higher.
Motley Foollast month
Why CRISPR Therapeutics Slipped 10% on Thursday
News from another company could be sparking a sell-off.
Zackslast month
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
ACCESSWIRElast month
Record Revenue Growth & Imminent Nasdaq Listing Could Spell Big Upside for Unknown Orgenesis (ORGS)
- NASDAQ up-listing may bring new institutional investors to the cell therapy manufacturer Orgenesis (ORGS), which has seen increased interest already as the company executes on their business model in ...
ACCESSWIRElast month
Wired News – Voyager Therapeutics Declared Longer-term Data from Phase-1b Trial Of VY-AADC for Advanced Parkinson’s Disease
Stock Monitor: Editas Medicine Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: VYGR ...
Zacks2 months ago
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
Zacks2 months ago
Healthcare Heroes That Aren't Done Yet
Healthcare Heroes That Aren't Done Yet
Thomson Reuters StreetEvents2 months ago
Edited Transcript of EDIT earnings conference call or presentation 6-Mar-18 10:00pm GMT
Q4 2017 Editas Medicine Inc Earnings Call
Motley Fool2 months ago
Editas Medicine Delivers Another Strong Quarter
With several promising irons in the fire, the biotech specialist laid out exciting goals for the future.
Motley Fool2 months ago
Here's Why Editas Medicine Inc. Ticked Up Today
Post-earnings call upgrades are providing some lift.
Associated Press2 months ago
Editas reports 4Q loss
The Cambridge, Massachusetts-based company said it had a loss of 84 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
GlobeNewswire2 months ago
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
EDIT-101 for Leber Congenital Amaurosis type 10 on track for mid-2018 Investigational New Drug filing. Expecting at least five clinical-stage programs by end of 2022 as part of EM22 five-year goals. Year-end ...
ACCESSWIRE2 months ago
Editas Medicine, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Editas Medicine, Inc. (NASDAQ: EDIT ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018, at 5:00 PM Eastern Time. ...
Benzinga2 months ago
Editas Medicine Q4 Earnings Preview
On Tuesday, Editas Medicine, Inc. - Common Stock (NASDAQ: EDIT ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Wall Street analysts see Editas ...
Motley Fool2 months ago
3 Growth Stocks That Could Put Facebook's Returns to Shame
Facebook stock has been a big winner, but these three stocks could post even better returns.
Investor's Business Daily2 months ago
Pentagon Lab Worries About CRISPR Bioattack As China Seeks Genome Lead
Hypersonic weapons and artificial intelligence may get the headlines, but the head of Darpa is concerned about potential biological attacks that use new gene-editing technology.
GlobeNewswire2 months ago
Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases
CAMBRIDGE, Mass., Feb. 28, 2018-- Editas Medicine, Inc., a leading genome editing company, today announced the Company has joined forces with 30 million Americans and health care advocates around the world ...
Yahoo Finance Video4 days ago
Big Week in Tech for Amazon, Alphabet and Microsoft
The next week will be crucial for one of the most important market sectors - Tech. Big earnings on the way from Amazon, Alphabet, and Microsoft - but lets start with Netflix. Shares popping THIS week as earnings and subscriber numbers top estimates.